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Abstract. Aim: To assess HER-2 and p-AKT expression in
upper urinary tract urothelial carcinoma (UTUC) in order
to determine their value as prognostic factors of tumour
progression and cancer-specific survival. Patients and
Methods: One hundred consecutive UTUC patients were
retrospectively included, between 1990-2004, in 4 tissue
microarrays for immunostaining. Median follow-up: 33.03
months. Results: Positive HER-2 expression was found in 10
cases and cytoplasmic p-AKT expression in 84 cases; the
expression intensity was strong: 30 cases, moderate: 28 and
weak: 26. Nuclear p-AKT expression was found in 6
patients: 1 with strong, and 5 with moderate intensity.
Nuclear p-AKT expression was an independent factor for
tumour progression (HR=4.145, p=0.013), together with
grade (HR=4.557, p=0.009) and stage (HR=2.085,
p=0.003). In cancer-specific survival analysis, nuclear p-
AKT expression (HR=4.268, p=0.017), together with grade
(HR=5.214, p=0.035) and stage (HR=2.666, p=0.002) were
identified as independent prognostic factors. Conclusion:
Nuclear p-AKT expression together with stage and grade
constitute independent prognostic factors for tumour
progression and cancer-specific survival. 
Upper urinary tract urothelial carcinoma (UTUC) is an
infrequently occuring tumour, with an incidence of 0.7-1.1
per 100,000 population per year in Europe, and has increased
slightly over the last 30 years (1). It represents 5% of all
patients with urothelial cancers (2). Eighty percent of
UTUCs are detected after bladder cancer diagnosis. Two
thirds of these patients are at risk of developing other
urothelial tumours in the future (1). Radical surgery, such as
nephroureterectomy or partial ureterectomy, is the accepted
treatment for localized UTUC. Pathological stage and
tumour grade are associated with distant metastasis, but they
are insufficient to predict the individual outcome of these
tumours (3). More accurate knowledge regarding the
biological behavior of tumours would allow tailored
treatment schedules to be offered to patients, in an attempt
to increase survival and reduce morbidity.
The expression or activation of epidermal growth factor
receptor ERB-B is altered in many epithelial tumours, and
clinical studies indicate that they have important roles in
tumour aetiology and progression (4). The ERB-B family
comprises 4 receptors: EGFR (HER-1), HER-2 (ERB-B2),
HER-3 and HER-4. All members have an extracellular ligand-
binding region, a single membrane-spanning region and
tyrosine-kinase-containing domain. Ligand binding to ERB-B
receptors induces the formation of receptor homo- and hetero-
activation of the intrinsic kinase domain, resulting in
phosphorylation on specific tyrosine residues within the
cytoplasmic tail. These phosphorylations serve as docking sites
for a range of proteins, the recruitment of which leads to the
activation of intracellular signalling pathways (5). The signal
transduction pathways activated by pEGFR play important
roles in various cellular processes, such as cell proliferation,
differentiation, adhesion, migration and apoptosis (6).
HER-2 has been shown to be important in tumour growth
and development (7). Activated HER-2 stimulates the
phosphoinositide-3 kinase (PI3K)/AKT pathway. The
activation of this pathway initialises the recruitment of
different adaptor proteins, which bind to different
phosphotyrosine residues of the cytoplasmic tail of EGFR,
and continues with a high network of enzymes, proteins and
small-molecule secondary messengers (8). Activated AKT
(p-AKT) can be internalized in the cellular nucleus and can
modulate the function of numerous substrates related to cell
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cycle progression. Several mediators within HER-2 and
PI3K/AKT have been studied in urological solid tumours (9,
10). Dysregulation of this pathway has been suggested to
contribute to the pathogenesis and progression of different
human malignancies resulting in enhanced invasiveness,
migration, proliferation and prolonged survival of somatic
cells (11). In this study, HER-2 and AKT expression in
UTUC was assessed in order to determine their value as a
prognostic factor of tumour progression and cancer-specific
survival.
Patients and Methods
Patients. One hundred consecutive patients with UTUC who
underwent nephroureterectomy (n=98) or partial ureterectomy (n=2)
at the Hospital Clinic of Barcelona between 1990 and 2004 were
retrospectively included in this study. The only exclusion criterion
was the lack of tissue from the archive blocks for inclusion in the
microarray. The median age of the patients was 69.8 years (range 45-
101 years) and the median overall follow-up time was 33.03 months
(range 0.3-182.7 months). The distribution per stage and grade was
as follows: 14 pTa, 24 pT1, 21 pT2, 28 pT3, 13 pT4 and 9 grade I,
44 grade II and 47 grade III. The location of the tumour was the
renal pelvis in 75 patients and the ureter in 25. Thirty patients with
UTUC had a previous history of bladder cancer. Twenty-nine of them
had non muscle-invasive bladder cancer (19 Ta and 10 T1). There
was only one case of muscle-invasive bladder cancer which
underwent radical cystectomy before developing UTUC. The
pathological analysis of the bladder revealed a pT2 N0 tumour. This
patient developed UTUC after 26 months of surveillance, but
presented with no tumour progression after 72 months of follow-up.
Patients were followed-up postoperatively at 3-month intervals for
the first year, and 6-month intervals for the next 2 years, and if they
were disease-free after 3 years, follow-up examinations were made
yearly. Abdominal and pelvic CT Scan, cytology and cystoscopy
were used in the patient follow-up. 
Tumours were considered to be progressing when distant
metastasis or pathological nodes developed during the follow-up
period. Tumours were graded and classified according to the World
Health Organisation (12) and the TNM classification of the
International Union Against Cancer (13). Samples were obtained
under institutional review board-approved protocol. 
Tissue specimens and tissue microarrays (TMA) construction.
Haematoxylin/eosin-stained sections from the formalin-fixed
paraffin-embedded cases of UTUC were reviewed and a
representative tumour area was selected for each case. Two 2 mm
tissue cores were taken from each targeted lesion and placed into
four TMA paraffin blocks. First, second and third TMA
comprised a cohort of 30 individual tumour samples (60 cores
each) and the fourth TMA contained 10 individual tumour
samples (20 cores each).
TMA tissue blocks were cut 5 μm thick, and a representative
section of each block was stained with haematoxylin and eosin for
tumour verification. 
Immunohistochemistry analysis and evaluation. The following
antibodies were used in this study: rabbit polyclonal anti-human 
c-erbB-2 Oncoprotein (ref. A0485; Dako (Denmark), dilution 1:700)
and rabbit polyclonal phospho-AKT antibody (ref. 9277; Cell
Signaling (Boston, USA), dilution 1:50). 
Four-micron paraffin-embedded sections were used for
immunohistochemical examination. Only cases with 2 preserved
cores were considered for evaluation. After paraffin removal and
hydration, antigen retrieval for c-erbB-2 was performed using a
pressure cooker in 10 mM citrate buffer (pH 6.0). Slides were then
incubated with the primary antibody for 30 min at room temperature
and rinsed. Peroxidase-labelled polymer conjugated to antirabbit
method (DAKO EnVision+ System; Dako Corporation, Boston,
MA, USA) was used to detect antigen-antibody reaction. Sections
were visualized with 3,3’-diaminobenzidine as a chromogen and
counterstained with Mayer’s hematoxylin.
Positive and negative controls were included in each slide run.
Positive controls were carried out for c-erbB-2 and p-AKT
consisting of breast carcinoma, according to the manufacturer’s
recommendations. Negative controls were carried out by omitting
the primary antibody.
Staining evaluation was carried out by two independent
observers. The agreement between both observers was >90%. Cases
of disagreement were reviewed jointly to reach a consensus score.
Immunostaining of HER-2 showed a membranous pattern. For 
p-AKT, staining was found in the cytoplasm and nucleus.
HER-2 staining was scored according to the Herceptest protocol
(14) and considered positive when >10% of tumour cells showed
moderate or strong membranous staining. The average score
considered was the maximum expression of two scores. The
evaluation of p-AKT expression was based on the method described
by Pantuck et al. (15), which considered staining intensity as 0:
negative, 1: weak, 2: moderate, 3: strong and staining frequency as
a percentage of positive cells. Intensity and frequency staining were
evaluated in both cytoplasm and nucleus. For the statistical analysis,
nuclear or cytoplasmic p-AKT expression was defined as being
present when more than 10% of the tumour cells were stained.
Statistical analysis. The probabilities of progression-free survival and
cancer-specific survival were calculated using Kaplan-Meier curves.
Statistical differences were identified by the log-rank test. Hazard
ratios (HRs) and their confidence interval (CIs) were calculated.
Spearman test was used for correlations. In the multivariate analysis,
forward stepwise Cox regression was performed. Statistical
significance was established at a p-value of 0.05, and 95% CIs for
the item are presented. SPSS 12.0 software (SPSS, ©SPSS Inc,
Chicago, IL, USA) was used for statistical analysis.
Results
Inmunohistochemistry results. HER-2-positive expression
was present in 10 cases (10%). Cytoplasmic p-AKT
expression was found in 84 cases (84%). Of these, 30
presented strong intensity, 28 moderate intensity and 26
weak intensity. Nuclear p-AKT expression was found in 6
patients (6%). One of them presented strong intensity and
five moderate intensity (Figure 1). Molecular expression
according to tumour stage and grade are shown in Table I.
Correlations between HER-2 and p-AKT. HER-2 expression
correlated with nuclear p-AKT expression (R=0.386,
p<0.001), tumour grade (R=0.355, p<0.001) and positive
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lymph nodes (R=0.287, p=0.005). Cytoplasmic expression
of p-AKT correlated with nuclear p-AKT expression
(R=0.204, p=0.045). p-AKT nuclear expression correlated
with tumour grade (R=0.245, p=0.017).
Tumour progression. The two cases treated with partial
ureterectomy did not develop tumour progression. Overall,
28 patients developed tumour progression after a median
overall follow-up of 33.03 (0.3-182.7) months. The median
time of tumour progression was 26.07 (0.6-182.7) months.
Thirteen patients had positive lymph nodes at the time of
diagnosis. They received adjuvant treatment (platin-based
regimen), but all of them developed tumour progression
during the follow-up. Five-year disease-free progression of
the series was 68.1%. 
Results from the univariate analysis show that stage, grade
and nuclear p-AKT expression are prognostic factors for
tumour progression (Table II). Tumour progression-free
survival analysis showed a significant difference between
patients with tumours which expressed nuclear p-AKT and
those that did not (Figure 2). The 5-year tumour progression-
free survival was 67.6% vs. 0% (p<0.001) for negative and
positive p-AKT, respectively. For histological grade and
pathological stage, the 5-year tumour progression-free
survival was 100%, 85.3% and 33.2% for grade I, II, III and
95.2%, 80%, 81%, 36% and 25.2% for pTa, pT1, pT2, pT3
and pT4, respectively (Figure 2).
In the multivariate regression analysis, the independent
predictive variables for tumour progression were histological
grade (HR 4.557, p=0.009), pathological stage (HR=2.085,
p=0.003) and nuclear p-AKT expression (HR 4.145,
p=0.013) (Table II).
Cancer-specific survival. The two cases treated with partial
ureterectomy did not die as a result of cancer. Overall, 20
patients died due to UTUC during the surveillance period.
Five-year cancer-specific survival of the series was 72.9%. 
Nuclear p-AKT expression and pathological stage were
indicative factors of cancer-specific survival in the univariate
analysis (Table II). Among the molecular markers, a
comparison of the 5-year cancer-specific survival showed
that only patients with nuclear expression of p-AKT had
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Table I. Molecular expression according to tumor stage and grade. 
Patients HER-2 Cytoplasmatic p-AKT Nuclear p-AKT
Positive Negative Expression No expression Expression No expression
Stage (TNM)
pTa 14 1 13 11 3 0 14
pT1 24 1 23 21 3 0 24
pT2 21 1 20 18 3 2 19
pT3 28 5 23 24 4 3 25
pT4 13 2 11 10 3 1 12
Grade
GI 9 0 9 7 2 0 9
GII 44 0 44 38 6 1 43
GIII 47 10 37 39 8 5 42
Table II. Univariate and multivariate analysis for tumor progression and cancer specific survival in patients with UUTC.
Variables Tumour progression Cancer-specific survival 
Univariate Multivariate Univariate Multivariate
HR p-Value HR p-Value HR p-Value HR p-Value
Nuclear p-AKT expression 7.213 0.018* 4.145 0.013* 14.413 0.005* 4.268 0.017*
Histological grade 4.605 0.011* 4.557 0.009* 4.612 0.066 5.214 0.035*
Pathological stage 2.963 0.007* 2.085 0.003* 3.632 0.001* 2.666 0.002*
Positive lymph nodes 1.380 0.183 -- -- 1.486 0.131 -- --
Cytoplasmic p-AKT expression 0.647 0.437 -- -- 1.159 0.830 -- --
Adjuvant treatment 0.576 0.310 -- -- 0.197 0.051 -- --
HER-2 expression 0.424 0.293 -- -- 0.360 0.254 -- --
statistically significantly lower probability of cancer-specific
survival (0% vs. 78.3%) (p<0.001). The 5-year cancer-
specific survival was 100%, 93% and 44.5% for histological
grade I, II, III and 100%, 95.2%, 89.5%, 52% and 18.3% for
pTa, pT1, pT2, pT3 and pT4, respectively (Figure 2).
In the multivariate regression analysis, the independent
predictive variables of cancer-specific survival were
histological grade (HR 5.214, p=0.035), pathological stage
(HR 2.666, p=0.002) and nuclear p-AKT expression
(HR=4.268, p=0.017) (Table II).
Discussion and Conclusion
UTUC is considered to have a worse prognosis than
urothelial bladder cancer. In the patient series presented here,
one quarter of these patients presented with tumour
progression after a 4-year follow-up. Since tumour stage and
grade are the only established prognostic factors for UTUC,
this study focused on a search for biomarkers to improve and
personalise prognosis of this disease. 
The AKT pathway is de-regulated in many types of cancer
(11). AKT is a serine protein kinase involved in several
carcinogenesis mechanisms such as cell survival, protein
synthesis, apoptosis, genetic instability and cell cycle. This
protein is of considerable importance due to the development
of kinase inhibitors that are able to reduce tumour growth
successfully. The AKT pathway can be activated, amongst
others, by HER-2, a receptor related to tumour growth and
development. In this study, p-AKT and HER-2 expression were
evaluated by immunohistochemical analysis in a series of 100
UTUC patients in order to determine their value as a prognostic
factor of tumour progression and cancer-specific survival.
Several studies have explored HER-2 expression and its
role as a prognostic factor in bladder cancer, obtaining a
discordant percentage of HER-2 staining in their samples and
concluding a distinct association between this molecule and
its prognostic implication (10, 16-19) (Table III). It is likely
that the use of different staining protocols and scoring
methods or the small sample size could be responsible for
these discrepancies. However, it is notable that several of
these studies identified a correlation between HER-2
expression, histological grade (17) and positive lymph nodes
(19), in accordance with the results in UTUC presented here.
In fact, HER-2 receptor is used as a target for the anti-HER-
2 antibody (trastuzumab) treatment in many tumours (20).
Also in accordance with the results presented here, neither
Wulfing et al. (19) nor Jimenez et al. (18) found any
association between HER-2 expression and disease-free or
cancer-specific survival.
In contrast, there are only a few published reports in the
literature reporting HER-2 expression in UTUC. Tsai et al.
(9) studied HER-2 expression by immunohistochemical
analysis (n=94 patients) and showed that this molecule was
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Figure 1. HER-2 and p-AKT expression in UTUC samples. A: Positive
HER-2 expression. B: Positive cytoplasmic p-AKT expression (70% of
the whole sample was stained with an intensity of 2). C: Positive nuclear
p-AKT expression (80% of the whole sample was stained with an
intensity of 3. The images also shows cytoplasmic expression of p-AKT).
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Figure 2. Tumor progression-free survival (A) and cancer-specific survival (B) distribution of patients (n= 100) with UTUC according to (1) nuclear
p-AKT expression, (2) tumor histological grade and (3) tumor pathological stage.
over-expressed in 13.8% of the UTUC samples. These
authors showed that HER-2 overexpression was significantly
associated with tumour invasiveness. The data presented here
are similar, since HER-2 overexpression was found in 10%
of the samples and this was correlated not only with tumour
stage but also with tumour grade and positive lymph nodes.
Moreover, Tsai et al. (9) described in univariate and
multivariate analyses that tumour stage and HER-2 expression
were independent predictors of disease progression, cancer-
specific and overall survival. In contrast, this study did not
find HER-2 expression to be an independent factor of either
tumour progression or cancer-specific survival. It is likely that
differences in the surveillance period, or the small size of the
patient series, as well as the use of a tissue microarray
platform for the immunohistochemical analysis avoiding the
bias of the case-by-case studies, could account for these
discrepancies. Interestingly, in this study all the patients who
expressed HER-2 had GIII tumours. However, these patients
did not show statistical differences in cancer-specific survival
and tumour progression compared to those GIII patients who
did not express HER-2.
It is widely reported that AKT, a serine protein kinase
involved in several carcinogenesis mechanisms, is expressed
in renal cell carcinoma (15, 21), but its expression has not
been described in either UTUC or bladder cancer. A recent
publication including 386 patients of renal cell carcinoma
(21) concluded that increased nuclear and cytoplasmic p-
AKT expression was an independent prognostic factor for
patient survival. In this study of UTUC, no association
between cytoplasmatic p-AKT expression and tumour
progression or cancer-specific survival was found. However,
nuclear p-AKT expression was found to be an independent
prognostic factor for tumour progression and cancer-specific
survival. Those 6 patients whose expressed nuclear p-AKT
had tumours higher probability of tumour progression
(HR=4.145) and cancer-specific mortality (HR=4.268).
Despite the low number of tumours expressing nuclear p-
AKT, this subgroup of patients may be at a very high risk
of morbidity, making them a target group for the use of the
most aggressive therapies. Nuclear p-AKT expression was
correlated with HER-2 expression and histological grade.
HER-2 expression was positive in 50% of patients whose
tumours expressed nuclear pAKT. The association between
HER-2 and cytoplasmic p-AKT and its prognostic impact
has been described in gynaecological cancer (7), but it had
never been studied in UTUC.
To the Authors’ knowledge, the prognostic significance of
nuclear p-AKT in UTUC has not been reported to date.
Although nuclear p-AKT expression is infrequent in UTUC
samples, this study found that it is able to identify a high-
risk subgroup of patients and its staining can be used as a
prognostic factor for tumour progression and cancer-specific
survival. Consequently, this molecule could be a target
candidate for new therapeutic strategies in UTUC. However,
these results will require validation in a larger and
independent series of patients prior to clinical usefulness. In
addition, it is necessary to continue searching for new
markers in order to improve our knowledge about the nature,
development and behavior of these tumours.
In conclusion, these data suggest that nuclear p-AKT
expression in UTUC, together with histological grade and
pathological stage, constitute an independent prognostic
factor of tumour progression and cancer-specific survival.
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Table III. HER-2 expression in several studies of bladder cancer.
Study n HER-2 HER-2 associations
Expression Tumor Related p-Value Positivity staining criteria
(% patients) HER-2 variables
expression
Jimenez et al. (18) 80 28% Negative HER-2 expression Complete and strong membranous 
in lymph node metastases p=0.009 pattern with moderate intensity
Wester et al. (16) 21 81% Positive Distant metastasis p=0.002 Semi-quantitative: > 2/3 cells stained and 
++ or +++ staining intensity
Wulfing et al. (19) 127 74.8% Positive Lymph node metastases
Distant metastasis p=0.06 Herceptest
p=0.002
Gardmark et al. (10) 90 79% Positive Distant metastasis p=0.01 Target score criteria and Herceptest
Jalali et al. (17) 75 37.3% Positive Tumour grade p=0.002 Food and Drug administration approved criteria
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